Digital TwinMarch 2026
Reducing Phase 1 Failure Rates with Agent-Based Digital Twins
Agent-based modeling (ABM) is emerging as a critical tool for preclinical de-risking. By simulating immune cell dynamics in silico, research teams can predict therapeutic outcomes before animal studies, reducing costs by up to 40%.
JFInnova Perspective
Our Spatial ABM Simulator — live on this website — demonstrates exactly this capability: drug-dependent immune dynamics, disease progression modeling, and split-view comparison between treated and untreated scenarios.
References
1
Digital twin clinical trial simulation